Characteristics of CliniMACS® System CD34-Enriched T Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 690-697

  Keever Taylor, Carolyn A ^a   Devine, Steven M ^b   Soiffer, Robert J ^c   Mendizabal, Adam ^d   Carter, Shelly ^d   Pasquini, Marcelo C ^a   Hari, Parameswaran N ^a   Stein, Anthony ^e   Lazarus, Hillard M ^f   Linker, Charles ^g   Goldstein, Steven C ^h   Stadtmauer, Edward A ^h   O'Reilly, Richard J ⁱ  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d EMMES CORPORATION   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; Blood and Marrow Transplant Clinical Trials Network; Clinical trial; Graft processing; T cell depletion

Indexed keywords

CD34 ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; LABORATORY DEVICE; MALE; MONOCYTE; MULTICENTER STUDY; STEM CELL MOBILIZATION; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIGENS, CD3; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; BONE MARROW TRANSPLANTATION; FLOW CYTOMETRY; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMAGNETIC SEPARATION; LEUKEMIA, MYELOID, ACUTE; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MULTIVARIATE ANALYSIS; SIBLINGS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859878721     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.08.017     Document Type: Article

References (17)

1. Aversa F., Reisner Y., Martelli M.F. The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2008, 40:8-12.
2. + progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001, 27:777-783.
3. Papadopoulos E.B., Carabasi M.H., Castro-Malaspina H., et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998, 91:1083-1090.
4. Soiffer R.J., Fairclough D., Robertson M., et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 1997, 89:3039-3047.
5. Davies S.M., Wang D., Wang T., et al. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 2009, 15:360-366.
6. Wagner J.E., Thompson J.S., Carter S.L., Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
7. Devine S.M., Carter S., Soiffer R.J., et al. Low risk of chronic graft versus host disease and relapse associated with T-cell depleted peripheral blood stem cell transplantation for acute myeloid leukemia in first remission: results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303. Biol Blood Marrow Transplant 2011, 17:1343-1351.
8. + cells using the CliniMACS device. J Hematother 1999, 8:209-218.
9. Slaper-Cortenbach I.C., Wijngaarden-du Bois M.J., de Vries-van Rossen A., et al. The depletion of T cells from haematopoietic stem cell transplants. Rheumatology (Oxford) 1999, 38:751-754.
10. Braakman E., Schuurhuis G.J., Preijers F.W., et al. Evaluation of " out-of-specification" CliniMACS CD34-selection procedures of hematopoietic progenitor cell-apheresis products. Cytotherapy 2008, 10:83-89.
11. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23:3447-3454.
12. Ringhoffer M., Wiesneth M., Harsdorf S., et al. CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. Br J Haematol 2004, 126:527-535.
13. Zinno F., Landi F., Aureli V., et al. Positive immunomagnetic CD34(+) cell selection in haplo-identical transplants in beta-thalassemia patients: removal of platelets using an automated system. Cytotherapy 2010, 12:60-66.
14. Del Fante C., Perotti C., Viarengo G., et al. Immunomagnetic cell selection performed for HLA haploidentical transplants with the CliniMACS device: effect of additional platelet removal on CD34+ cell recovery. Stem Cells Dev 2005, 14:734-739.
15. Sutherland D.R., Anderson L., Keeney M., Nayar R., Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996, 5:213-226.
16. Keeney M., Chin-Yee I., Weir K., Popma J., Nayar R., Sutherland D.R. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998, 34:61-70.
17. Baech J., Johnsen H.E. Technical aspects and clinical impact of hematopoietic progenitor subset quantification. Stem Cells 2000, 18:76-86.